$JAGX Possible Pattern Play Out: 15 Min Timeframe Curious to see wether the current C&H pattern will play out.
JAGX trade ideas
$JAGXJust a prediction. Taking into consideration the conference meetings jaguar has from the 11th - 16th. It's entirely possible.
Entry: 3.00 - 3.40
Exit: 6.00 - 6.11
Intraday trade for those who don't already have there long term shares.
overnight holdjust one things they have planned for monday's conference can shoot this stock into the next galaxy.
JAGXJAGX = Happy New Year to all my followers and not only ... I wanted to give you a small gift for the beginning of the year ... here the risk of return is very very favorable ... We have a very long-term bowl that in a short time has given strong signals awakening ... you see the volumes and more, it presents a very very promising conformation .. If we add that a giant like Roche has set his sights on the Juagar team ... the game can be at hand ... .BEWARE IN THE NEXT DAYS ABOVE $ 1 can fly to $ 4 in no time .... Why you ask? .... the graph is the first catalyst that gives you long-term information ... and here you are I have drawn them to understand ... Happy New Year my friends and haters.
JAGX LONGThis is an incredible long opportunity, the stock shows huge institutional interest, while also being hugely oversold, combined with the recent breakout. this is exactly what I have been waiting for, this has an outstanding risk to reward ratio.
JAGX looks primed for a move to the upsideJAGX just formed a smaller cup and handle and completed a measured move to the upside. On the larger time frame it appears to be curling the handle for another measured move to the upside bringing it to the gap fill in the 2.24 - $2.50 range
$JAGX Jaguar Health $3.29 target 🎯
there look's to be some fuel left in this rally, above this level there is very little price resistance,
so we aim for the 100ma as a possible target
$JAGX Jaguar Health Potential for Major Breakout
Alerts et for break above $ 1.30
Opens up a move to much higher , use pivots as targets
Previous targets hit , big winner for us
JAGX Signs Second Agreement for $6 Mil Non-dilutive FinanciningJaguar Health Signs Second Agreement for $6 Million Non-dilutive Financing Transaction Involving the Sale of Royalty Rights Related to Future Mytesi (Crofelemer) and Lechlemer Revenue Stream
Jaguar Health, Inc. has signed an agreement (the "Agreement") with a secured lender (the "Lender") for a non-dilutive royalty financing transaction, pursuant to which Jaguar would sell to the Lender for an aggregate purchase price of $6 million (the "Royalty Purchase Price") a royalty interest entitling the Lender to receive 2.0x the Royalty Purchase Price of future royalties of Mytesi® (crofelemer) and lechlemer and certain up-front license fees and milestone payments from licensees and/or distributors as well as any interest, fees, and charges in accordance with the terms set forth in the Agreement (the "Royalty Repayment Amount"), and to pay interest on the Royalty Repayment Amount at the rate of ten percent per annum until the same is paid in full.
No royalty payments due for 18-24 months
Jaguar intends to use the proceeds to support regulatory activities associated with the Company's development pipeline
This $6 million royalty financing transaction follows an earlier $6 million royalty transaction consummated in October 2020 with an affiliate of the Lender.
We may consider entering into similar agreements in the future and of course business development relationships as additional sources of non-dilutive funding."
finance.yahoo.com
Jaguar Health, Inc. 15% upsideJaguar Health, Inc. is a commercial stage pharmaceuticals company, which engages in the development of gastrointestinal products. Its products include Canalevia, Equilevia, and Neonorm. It operates through the Human Health and Animal Health segments. The Human Health segment manufactures human products and the ongoing advertising of Mytesi, which is used for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The Animal Health segment commercializes prescription and non-prescription products for companion and production animals. The company was founded by Lisa A. Conte on June 6, 2013 and is headquartered in San Francisco, CA.
Jaquar Health Inc Potential Breakout Jaguar Health, Inc. is a commercial stage pharmaceuticals company, which engages in the development of gastrointestinal products. Its products include Canalevia, Equilevia, and Neonorm. It operates through the Human Health and Animal Health segments. The Human Health segment manufactures human products and the ongoing advertising of Mytesi, which is used for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The Animal Health segment commercializes prescription and non-prescription products for companion and production animals. The company was founded by Lisa A. Conte on June 6, 2013 and is headquartered in San Francisco, CA.
BREAKOUT SETUP HERE - BASED ON PRIOR PRICE ACTIONstop loss set below moving averages - lots of explosive potential on this stock.
Jaguar Health to Host Investor Call Monday, November 16th at 8:30 a.m. Eastern Regarding Q3 2020 Financials & Business Updates
4:19 PM ET 11/10/20 | Dow Jones
Related Quotes
10:44 AM ET 11/11/20
Symbol Last % Chg
JAGX
0.21 3.80%
Real time quote.
Company Plans to File Q3 2020 10-Q on November 16, 2020
SAN FRANCISCO, CA / ACCESSWIRE / November 10, 2020 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that Company management will host a conference call on Monday, November 16, 2020 at 8:30 a.m. Eastern Time to review third-quarter 2020 financials and provide business updates.
Dial-In Instructions for Investor Call
When: Monday, November 16, 2020 at 8:30 a.m. Eastern Time
Dial-in (US Toll Free): 866-548-4713
Dial-in (International): 323-794-2093
Conference ID number: 8490376
Live webcast on the investor relations section of Jaguar's website (click here)
Replay Instructions for Investor Call
Dial-in (US Toll Free): 844-512-2921
Dial-in (International): 412-317-6671
Replay Pin Number: 8490376
Replay of the webcast on the investor relations section of Jaguar's website (click here)
About Jaguar Health, Inc. and Napo Pharmaceuticals, Inc.
Jaguar Health, Inc. is a commercial stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Our wholly owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary plant-based human gastrointestinal pharmaceuticals from plants harvested responsibly from rainforest areas. Our Mytesi(R) (crofelemer) product is approved by the U.S. FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy and the only oral plant-based prescription medicine approved under FDA Botanical Guidance.
For more information about Jaguar, please visit jaguar.health. For more information about Napo, visit www.napopharma.com.
About Mytesi(R)
Mytesi(R) (crofelemer) is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART). Mytesi(R) is not indicated for the treatment of infectious diarrhea. Rule out infectious etiologies of diarrhea before starting Mytesi(R) . If infectious etiologies are not considered, there is a risk that patients with infectious etiologies will not receive the appropriate therapy and their disease may worsen. In clinical studies, the most common adverse reactions occurring at a rate greater than placebo were upper respiratory tract infection (5.7%), bronchitis (3.9%), cough (3.5%), flatulence (3.1%), and increased bilirubin (3.1%).
More information and complete Prescribing Information are available at Mytesi.com. Crofelemer, the active ingredient in Mytesi(R) , is a botanical (plant-based) drug extracted and purified from the red bark sap of the medicinal Croton lechleri tree in the Amazon rainforest. Napo has established a sustainable harvesting program for crofelemer to ensure a high degree of quality and ecological integrity.
Forward-Looking Statements
Certain statements in this press release constitute "forward-looking statements." These include statements regarding the expectation that Jaguar will host a conference call on November 16, 2020, and the expectation that the Company will file its quarterly report on Form 10-Q on November 16, 2020 for the quarterly period ended September 30, 2020. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
Contact:
Peter Hodge
Jaguar Health, Inc.
phodge@jaguar.health
Jaguar-JAGX
SOURCE: Jaguar Health, Inc.
View source version on accesswire.com:
www.accesswire.com
> Dow Jones Newswires
November 10, 2020 16:19 ET (21:19 GMT)
JAGX long based on volume Expected an increase in price 1.23/1.52 based on exit channel and news. Rounded bottom .
JAGX Would you buy something that was 10000x more expensive? Jaguar Health, Inc. is a commercial stage natural-products pharmaceuticals company, focuses on developing gastrointestinal products for human prescription use and animals worldwide.
July 20, 2020 : Jaguar Health, Inc. announced today that it has submitted to the U.S. Food and Drug Administration's Center for Veterinary Medicine the second-to-last required technical section to support approval of Jaguar's oral plant-based drug candidate Canalevia™ (crofelemer delayed-release tablets) to treat chemotherapy-induced diarrhea in dogs, although this filing was originally scheduled for submission by the end of August 2020.
More than 230,000 dogs in the U.S. receive chemotherapy treatment for various cancers each year, and roughly one in four (more than 50,000 dogs) will experience diarrhea as a side effect of treatment.
OASIS CAPITAL LLC REPORTS 9.99% PASSIVE STAKE IN JAGUAR HEALTH AS OF JULY 7- SEC FILING
Net Income $-38,540,000
Market Cap $42.15 million
Annual Sales $5.78 million
Debt-to-Equity Ratio 0.08
JAGX is a risky bet that can double your money in seconds.
Not trading advice.
If you are interested to test some amazing buy and sell indicators, which give the signal at the beginning of the candle, not at the end of it, just leave me a message.
#JAGX $JAGX To pursue goalsNASDAQ:JAGX
This stock has good quantities
The party has not started yet
Whoever has the patience will win this soon
Starting with a price over $ 0.567
Double bottom.Double bottom on descending volumes.
Tripple if we consider the lower prior bottom.
If confirmed, target = 0,73$
Potential Opportunity In $JAGXBBs Narrowing Into A Squeeze
Price Been Consolidating For Weeks
Looking For Breakout Once BBs Narrow Enough
Company Submitted Final FDA Approval File For Canalevia Product, Expect News Soon
Volume Picking Up
